PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer

• Abul Azad,
• Maryam Arshad,
• Daniele Generali,
• Katharina Feldinger,
• Merel Gijsen,
• Carla Strina,
• Mariarosa Cappelletti,
• Daniele Andreis,
• Russell Leek,
• Syed Haider,
• Pirkko‐Liisa Kellokumpu‐Lehtinen,
• Ioannis Roxanis,
• Adrian Llewellyn Harris,
• Abeer Mahmoud Shaaban,
• Heikki Joensuu,
• Anthony Kong

Affiliations

Abul Azad

Department of Oncology The Weatherall Institute of Molecular Medicine University of Oxford Oxford UK

Maryam Arshad

Institute of Genomic and Cancer Sciences Vincent Drive, University of Birmingham Birmingham UK

Daniele Generali

U.O. Multidisciplinare di Patologia Mammaria U.S Terapia Molecolare e Farmacogenomica A.O. Instituti Ospitalieri di Cremona Viale Concordia 1 Cremona Italy

Katharina Feldinger

Department of Oncology The Weatherall Institute of Molecular Medicine University of Oxford Oxford UK

Merel Gijsen

Department of Oncology The Weatherall Institute of Molecular Medicine University of Oxford Oxford UK

Carla Strina

U.O. Multidisciplinare di Patologia Mammaria U.S Terapia Molecolare e Farmacogenomica A.O. Instituti Ospitalieri di Cremona Viale Concordia 1 Cremona Italy

Mariarosa Cappelletti

U.O. Multidisciplinare di Patologia Mammaria U.S Terapia Molecolare e Farmacogenomica A.O. Instituti Ospitalieri di Cremona Viale Concordia 1 Cremona Italy

Daniele Andreis

U.O. Multidisciplinare di Patologia Mammaria U.S Terapia Molecolare e Farmacogenomica A.O. Instituti Ospitalieri di Cremona Viale Concordia 1 Cremona Italy

Russell Leek

Department of Oncology The Weatherall Institute of Molecular Medicine University of Oxford Oxford UK

Syed Haider

Department of Oncology The Weatherall Institute of Molecular Medicine University of Oxford Oxford UK

Pirkko‐Liisa Kellokumpu‐Lehtinen

Department of Oncology Tampere University Hospital and Tampere University Tampere Finland

Ioannis Roxanis

The Institute of Cancer Research London UK

Adrian Llewellyn Harris

Department of Oncology The Weatherall Institute of Molecular Medicine University of Oxford Oxford UK

Abeer Mahmoud Shaaban

Department of histopathology Queen Elizabeth Hospital Birmingham Birmingham UK

Heikki Joensuu

Department of Oncology Helsinki University Hospital and University of Helsinki Helsinki Finland

Anthony Kong

Department of Oncology The Weatherall Institute of Molecular Medicine University of Oxford Oxford UK